MedTrace Logo

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

NCT05957380 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-10-23

No results posted yet for this study

Summary

This study is a multi-center, double-blind, active-controlled, randomized, parallel clinical study to evaluate the efficacy and safety of DA-2803 in chronic hepatitis B subjects

Conditions

Interventions

DRUG

DA-2803

All participants are administered one tablet per day for 48 weeks

DRUG

DA-2803-R

All participants are administered one tablet per day for 48 weeks

DRUG

Placebo of DA-2803

All participants are administered one tablet per day for 48 weeks

DRUG

Placebo of DA-2803-R

All participants are administered one tablet per day for 48 weeks

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-20
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05957380 on ClinicalTrials.gov